期刊文献+

干扰素α治疗慢性粒细胞白血病患者浆细胞样树突细胞变化的观察 被引量:2

原文传递
导出
摘要 干扰素α(IFN-α)作为第一个被广泛研究的人类细胞因子,不仅对病毒感染性疾病确有疗效,而且对于多种恶性肿瘤也有一定疗效。IFN—α治疗慢性粒细胞白血病(CML)虽缓解率低,但对部分患者可达治愈的效果,这是除异基因造血干细胞移植(allo—HSCT)治疗以外,包括伊马替尼在内的其他一切治疗都无法达到的。现有研究表明,体内专职产生IFN—α的细胞是浆细胞样树突细胞(pDC),
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第7期482-484,共3页 Chinese Journal of Hematology
基金 基金项目:甘肃省科技计划项目(2GS054-A43-014-20)
  • 相关文献

参考文献8

  • 1Pfeffer LM,Dinarello CA,Herberman RB,et al.Biological properties of recombinant alpha-interferons:40th anniversary of the discovery of interferons.Cancer Res,1998,58:2489-2499.
  • 2Kantarjian HM,O'Brien S,Cortes J,et al.Complete eytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.Cancer,2003,97:1033-1041.
  • 3Liu YJ.IPC:professional type 1 interferon-producing cells and plasmacytoid cendritic cell precursors.Annu Rev Immunol,2005,23:275-306.
  • 4Bhatia R,Holtz M,Niu N,et al.Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.Blood,2003,101:4701 4707.
  • 5Rousselot P,Huguet F,Rea D,et al.Imatinib mesylate discontinuation in patients with chronic myelogunous leukemia in complete molecular remission for more than 2 years.Blood,2007,109:58-60.
  • 6Mohty M,Jarossay D,Lafage-Pochitaloff M,et al.Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment.Blood,2001,98:3750-3756.
  • 7Ito T,Amakawa R,Inaba M,et al.Differential regulation of human blood dendritic cell subsets by IFNs.J Immunol,2001,166:2961-2969.
  • 8Copland M,Fraser AR,Harrison SJ,et al.Targeting the silent minority:emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.Cancer Immunol Immunother,2005,54:297-306.

同被引文献9

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部